HBM (HKG:2142) has submitted an investigational new drug application to China's National Medical Products Administration for HBM9378, which is intended to treat chronic obstructive pulmonary disease, a Friday bourse filing said.
HBM9378 was developed by the drugmaker in partnership with Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990).